ArticleBlood2008
Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer.
Article in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 142 citations in OpenAlex.
- Plasma lipidomic and metabolomic profiles in high-grade glioma patients before and after 72-h presurgery water-only fasting.Molecular oncology · 2025Trial
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias.The Journal of experimental medicine · 2014Trial
- Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.Clinical and experimental immunology · 2014Trial
- Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cells.Neuro-oncology · 2025Article
- Plasma lipidomic signatures reveal age-associated patterns of septic shock risk and immune dysregulation in sepsis.Frontiers in immunology · 2025Article
- T Cells Dysfunction in Multiple Myeloma.ImmunoTargets and therapy · 2025Review
- Unconventional T cells in anti-cancer immunity.Frontiers in immunology · 2025Review
- "Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity.Cancer communications (London, England) · 2024Review
- Review
- Preliminary analysis of double-negative T, double-positive T, and natural killer T-like cells in B-cell chronic lymphocytic leukemia.Cancer medicine · 2023Article
- Novel lipid antigens for NKT cells in cancer.Frontiers in immunology · 2023Review
- Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.International journal of molecular sciences · 2022Review
- iNKT cells coordinate immune pathways to enable engraftment in nonconditioned hosts.Life science alliance · 2021Article
- The Role of NKT Cells in Glioblastoma.Cells · 2021Review
- Review
- Geniposide Ameliorates Liver Fibrosis Through Reducing Oxidative Stress and Inflammatory Respose, Inhibiting Apoptosis and Modulating Overall Metabolism.Frontiers in pharmacology · 2021Article
- Review
- Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.Frontiers in immunology · 2020Review
- Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy.Frontiers in cell and developmental biology · 2020Review
- Actors on the Scene: Immune Cells in the Myeloma Niche.Frontiers in oncology · 2020Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
CD1d-restricted T cells have been implicated in the pathogenesis of several chronic inflammatory states. However, the nature of the specific ligands recognized by these cells in vivo in patients with inflammatory or malignant diseases remains unknown. We took a biochemical approach to directly isolate and characterize the nature of CD1d-binding ligands from the plasma of myeloma patients. Characterization of these ligands revealed several lysophosphatidylcholine (LPC) species. Human LPC-CD1d dimer binding cells are T-cell receptoralphabeta(+) T cells but predominantly Valpha24(-)Vbeta11(-). Cytokine secretion by LPC-specific T cells is skewed toward IL-13 secretion, and the frequencies of these cells are increased in myeloma patients relative to healthy donors. These data identify a distinct population of human CD1d-restricted T cells specific for inflammation-associated lysolipids and suggest a novel mechanism for inflammation mediated immune regulation in human cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.